Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family-Reference-Cited by-同舟云学术

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Published:2016-08-22 Issue:17 Volume:59 Page:8103-8124
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Smaill Jeff B.¹²,Gonzales Andrea J.³,Spicer Julie A.¹²,Lee Helen³,Reed Jessica E.³,Sexton Karen³,Althaus Irene W.³,Zhu Tong³,Black Shannon L.¹,Blaser Adrian¹,Denny William A.¹²,Ellis Paul A.³,Fakhoury Stephen³,Harvey Patricia J.³,Hook Ken³,McCarthy Florence O. J.¹,Palmer Brian D.¹²,Rivault Freddy¹,Schlosser Kevin³,Ellis Teresa³,Thompson Andrew M.¹,Trachet Erin³,Winters R. Thomas³,Tecle Haile³,Bridges Alexander³

Affiliation:

1. Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

2. Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

3. Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105-1047, United States

Funder

Cancer Society of New Zealand

Maurice Wilkins Centre for Molecular Biodiscovery

Pfizer GRD

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00883

Reference84 articles.

1. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)

2. Integration of EGFR inhibitors with radiochemotherapy

3. Epidermal Growth Factor Receptor Targeting in Cancer

4. ERBB receptors and cancer: the complexity of targeted inhibitors

5. Front-line therapy in lung cancer with mutations in EGFR

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-11

2. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

3. Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment;Bioorganic Chemistry;2024-02

4. A multifaceted approach for the development of novel Hantzsch 1,4-dihydropyridines as anticancer agents: Rational design, parallel synthesis, analysis, cytotoxicity and EGFR/HER2 inhibition studies;Results in Chemistry;2024-01

5. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022;European Journal of Medicinal Chemistry;2023-11